Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Sales | 3,029 | 1,426 | 2,772 | 3,062 | 2,462 |
| Cost of Goods | 103 | 45 | 4 | 127 | 131 |
| Gross Profit | 2,926 | 1,381 | 2,768 | 2,935 | 2,332 |
| Operating Expenses | 16,969 | 18,510 | 17,531 | 20,089 | 13,662 |
| Operating Income | -13,940 | -17,084 | -14,759 | -17,027 | -11,200 |
| Other Income | 29 | 24 | 33 | 138 | 328 |
| Pre-tax Income | -13,910 | -17,060 | -14,725 | -16,889 | -10,872 |
| Net Income Continuous | -13,910 | -17,060 | -14,725 | -16,826 | -10,872 |
| Net Income | $-13,910 | $-17,060 | $-14,725 | $-16,826 | $-10,872 |
| EPS Basic Total Ops | -0.16 | -0.21 | -0.18 | -0.20 | -0.14 |
| EPS Basic Continuous Ops | -0.16 | -0.21 | -0.18 | -0.21 | -0.14 |
| EPS Diluted Total Ops | -0.16 | -0.21 | -0.18 | -0.20 | -0.14 |
| EPS Diluted Continuous Ops | -0.16 | -0.21 | -0.18 | -0.21 | -0.14 |
| EBITDA(a) | $-13,571 | $-16,732 | $-14,430 | $-16,736 | $-10,919 |